Dissecting Dendritic Cell Function in Autoimmune Diabetes
剖析自身免疫性糖尿病中树突状细胞的功能
基本信息
- 批准号:8119440
- 负责人:
- 金额:$ 32.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAdoptive TransferAntigen-Presenting CellsAntigensAutoimmune DiabetesAutoimmune DiseasesAutoimmune ProcessCD4 Positive T LymphocytesCell CommunicationCell physiologyChildhoodDendritic CellsDiphtheria ToxinDiseaseEnvironmentIn VitroInbred NOD MiceInsulin-Dependent Diabetes MellitusInterferonsLinkMediatingModelingMolecularMyelogenousPancreasPathogenesisPathologyPeripheralRegulationSeveritiesSignal TransductionStructure of beta Cell of isletT cell responseT-Cell ProliferationT-LymphocyteTestingTryptophan 2,3 DioxygenaseWorkconditioningimmunoregulationin vivoinhibitor/antagonistisletkiller T celllymph nodes
项目摘要
DESCRIPTION (provided by applicant): The autoimmune pathogenesis of Type 1 diabetes (T1D), the leading childhood autoimmune disease, is experimentally-modeled in the non-obese diabetic (NOD) mouse. NOD mouse studies have revealed that the so-called, diabetogenic, or disease-causing, T cells are central to the pathogenesis of T1D; yet, why these T cells are not effectively controlled via either central or peripheral mechanisms of tolerance is not fully understood. It is clear, however, that these T cells receive critical pro- and anti-proliferative signals from antigen presenting cells (APC) such as dendritic cells (DC), and that these T cell-APC interactions dramatically influence the effector T cell response to pancreatic beta cell antigens and the subsequent course of disease. Yet the molecular mechanisms underlying the control of diabetogenic T cells remain unsolved. Using a diphtheria toxin-mediated ablation model, we found that the myeloid dendritic cells (mDC) subset acts to promote T1D by priming diabetogenic T cells to pancreatic beta cell antigens in vivo. Conversely, depleting plasmacytoid DC (pDC) exacerbates the pathology- increasing both the number and severity of infiltrated islets, suggesting that, once activated, diabetogenic T cells are still under regulatory control by the pDC subset in vivo. Importantly, preliminary studies suggest a direct molecular mechanism, as the presence of intra-islet pDC correlated not only with reduced pathology but also with the localized expression of indoleamine 2,3-dioxygenase (IDO), a potent inhibitor of T cell proliferation. IDO is elicited from pDC by both type 1 and type 2 interferons (IFN). Natural Killer T (NKT) cells regulate diabetogenic CD4+ T cells in an IFN-9-dependent fashion. Using an adoptive transfer model, we found that CD4+ NKT cells are capable of regulating CD4+ diabetogenic effector T cells in vivo. This NKT cell-mediated immunoregulation occurs in the pancreas and pancreatic lymph nodes (PLN) and requires NKT cells to produce IFN-9. The apparent target of IFN-9 is host DC and not the diabetogenic T cells themselves, suggesting that the action of the NKT cells is indirect via conditioning of the host DC compartment. The most likely DC target is the pDC subset; and the most likely molecular effector is the induction of IDO. Preliminary studies suggest a causal link between NKT cells and pDC in the regulation of diabetogenic CD4+ T cells in the NOD mouse. Taken together, these findings have led us to hypothesize: (i) that NKT cells and pDC work in concert to regulate diabetogenic CD4+ T cells and modulate the tempo of insulitis in vivo; (ii) that pancreatic pDC can directly activate NKT cells to produce IFN-9; and (iii) that this IFN-9 induces pDC to in turn make IDO, which results in a localized environment that limits diabetogenic T cell proliferation. To test our hypotheses we propose the following two specific aims: Aim 1: To determine if pDC from the pancreas and PLN of NOD mice directly or indirectly activate NKT cells in vitro and in vivo. Aim 2: To determine if NKT cell-produced INF-9 and pDC-produced IDO establish a regulatory circuit that controls diabetogenic T cells in vivo.
描述(由申请人提供):1型糖尿病(T1D)的自身免疫发病机制是主要的儿童自身免疫性疾病,在非肥胖糖尿病(NOD)小鼠中进行了实验建模。NOD小鼠研究表明,所谓的致糖尿病或致病的T细胞是T1D发病机制的核心;然而,为什么这些T细胞不能通过中枢或外周耐受机制有效地控制,这一点尚不完全清楚。然而,很明显,这些T细胞接收来自抗原呈递细胞(APC)如树突状细胞(DC)的关键促增殖和抗增殖信号,并且这些T细胞-APC相互作用显著影响效应T细胞对胰腺β细胞抗原的反应和随后的疾病进程。然而,控制致糖尿病T细胞的分子机制仍未得到解决。利用白喉毒素介导的消融模型,我们发现髓样树突状细胞(mDC)亚群通过在体内将糖尿病源性T细胞导入胰腺β细胞抗原来促进T1D。相反,消耗浆细胞样DC (pDC)加剧了病理-增加浸润胰岛的数量和严重程度,这表明,一旦激活,糖尿病源性T细胞在体内仍受pDC亚群的调节控制。重要的是,初步研究表明了直接的分子机制,因为胰岛内pDC的存在不仅与病理减少有关,而且与吲哚胺2,3-双加氧酶(IDO)的局部表达有关,IDO是一种有效的T细胞增殖抑制剂。IDO可由1型和2型干扰素(IFN)诱导。自然杀伤T细胞(NKT)以ifn -9依赖性的方式调节糖尿病性CD4+ T细胞。通过过继转移模型,我们发现CD4+ NKT细胞能够在体内调节CD4+糖尿病效应T细胞。这种NKT细胞介导的免疫调节发生在胰腺和胰淋巴结(PLN)中,需要NKT细胞产生IFN-9。IFN-9的明显靶标是宿主DC,而不是致糖尿病性T细胞本身,这表明NKT细胞的作用是通过调节宿主DC隔室间接进行的。最可能的直流目标是pDC子集;最可能的分子效应是诱导IDO。初步研究表明,NKT细胞和pDC在NOD小鼠中调节致糖尿病CD4+ T细胞之间存在因果关系。综上所述,这些发现使我们假设:(i) NKT细胞和pDC协同调节糖尿病性CD4+ T细胞并调节体内胰岛素的速度;(ii)胰腺pDC可直接激活NKT细胞产生IFN-9;(iii) IFN-9诱导pDC反过来产生IDO,从而形成限制糖尿病性T细胞增殖的局部环境。为了验证我们的假设,我们提出了以下两个具体目标:目的1:确定NOD小鼠胰腺和PLN中的pDC是否直接或间接激活NKT细胞。目的2:确定NKT细胞产生的INF-9和pdc产生的IDO是否在体内建立了控制糖尿病性T细胞的调节回路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JONATHAN David KATZ其他文献
JONATHAN David KATZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JONATHAN David KATZ', 18)}}的其他基金
Manipulating DNA Damage-response Signaling for the Treatment of Type 1 Diabetes
操纵 DNA 损伤反应信号传导治疗 1 型糖尿病
- 批准号:
10319938 - 财政年份:2019
- 资助金额:
$ 32.62万 - 项目类别:
Manipulating DNA Damage-response Signaling for the Treatment of Type 1 Diabetes
操纵 DNA 损伤反应信号传导治疗 1 型糖尿病
- 批准号:
10091310 - 财政年份:2019
- 资助金额:
$ 32.62万 - 项目类别:
Dissecting Dendritic Cell Function in Autoimmune Diabetes
剖析自身免疫性糖尿病中树突状细胞的功能
- 批准号:
7741266 - 财政年份:2009
- 资助金额:
$ 32.62万 - 项目类别:
Dissecting Dendritic Cell Function in Autoimmune Diabetes
剖析自身免疫性糖尿病中树突状细胞的功能
- 批准号:
8308662 - 财政年份:2009
- 资助金额:
$ 32.62万 - 项目类别:
Dissecting Dendritic Cell Function in Autoimmune Diabetes
剖析自身免疫性糖尿病中树突状细胞的功能
- 批准号:
8517102 - 财政年份:2009
- 资助金额:
$ 32.62万 - 项目类别:
Using Genomics to Understand Autoimmune Diabetes
利用基因组学了解自身免疫性糖尿病
- 批准号:
7055244 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
Using Genomics to Understand Autoimmune Diabetes
利用基因组学了解自身免疫性糖尿病
- 批准号:
6637874 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
Using Genomics to Understand Autoimmune Diabetes
利用基因组学了解自身免疫性糖尿病
- 批准号:
6889265 - 财政年份:2002
- 资助金额:
$ 32.62万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 32.62万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 32.62万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 32.62万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 32.62万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 32.62万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 32.62万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 32.62万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 32.62万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 32.62万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 32.62万 - 项目类别:














{{item.name}}会员




